Projects

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study ...

The German Consortium for Hereditary Breast and Ovarian Cancer HBOC has been founded in 1996 by the German Cancer Aid and has been funded by the German Cancer Aid until recently. GC-HBOC currently comprises 17 university centers providing genetic counseling, histopathological and molecular tissue analysis, genetic testing, and specific structured surveillance programs for early cancer detection at each clinical unit, all based on defined standard operating procedures.

e:Med has the objective of establishing systems medicine in Germany. e:Med promotes system-oriented research into diseases in order to facilitate improved prevention, more comprehensive diagnostics and individually adjusted therapy schemes in individualized medicine. The program brings together scientists with molecular-genetic, clinical, mathematical and information technology expertise, with the objective of ensuring that research results quickly benefit patients.

In the interdisciplinary consortium HaematoSys partners from leading clinical haematooncological study groups, pathologists, geneticists, cell biologists as well as mathematicians, statisticians and bioinformaticians have joined forces.

Gastric cancer (GC) is a complex disease that represents the fifth most common malignancy in the world and the third leading cause of cancer death in both sexes. GC shows a high level of heterogeneity as well as a marked gender difference in incidence, GC affecting twice as many men as women. Chemotherapy (Ct) combined with surgery represents the standard of care for stages II-III GC, but the efficacy of such treatments is still limited for many patients. It is mandatory to develop novel therapeutic ...

The aim of the project is to investigate the range of residuals possible for people of similar height/weight.